MetaCap

Cocrystal Pharma (COCP) vs Marker Therapeutics (MRKR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cocrystal Pharma (COCP) has outperformed Marker Therapeutics (MRKR) over the past year, gaining 5.6% versus a gain of 2.8%. Over five years, MRKR leads with a -91.1% price change compared with -91.8% for COCP. Cocrystal Pharma is the larger company by market cap ($18.3 million vs $18.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COCP+5.56%MRKR+2.83%
+113%+42%-28%
Nov 21, 20251 yearNov 20, 2026
COCP-90.35%MRKR-91.62%
+24%-38%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COCP versus MRKR key metrics
MetricCOCPMRKR
Share price$0.95$1.09
Market cap$18.30M$18.17M
1-day change-2.05%-17.42%
YTD return-3.06%-26.85%
1-year return+5.56%+2.83%
5-year return-91.84%-91.14%
EPS (TTM)$-0.76$-0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.55M
Revenue growth (YoY)—-46.19%
Net income (latest FY)$-8.83M$-12.16M
Operating margin—-363.45%
Net margin—-342.96%
52-week high$2.03$2.46
52-week low$0.76$0.81
Distance from 52-week high-53.20%-55.69%
Analyst consensusnonenone
Avg. price target upside+847.37%+622.02%
Average volume40.65K711.96K
Shares outstanding19.26M16.67M
Employees105
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cocrystal Pharma

COCP stock →

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About Marker Therapeutics

MRKR stock →

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

COCP vs MRKR FAQ

Which is bigger, Cocrystal Pharma or Marker Therapeutics?

Cocrystal Pharma (COCP) is larger, with a market capitalization of $18.30M compared with $18.17M for Marker Therapeutics (MRKR).

Which stock has performed better over the past year, COCP or MRKR?

COCP returned +5.56% over the past 12 months, compared with +2.83% for MRKR (price return, excluding dividends). Past performance does not predict future results.

Are Cocrystal Pharma and Marker Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons